VitaHealth Analysis
Comprehensive Cancer – Male
VitaHealth Analysis Comprehensive Cancer – Male
What’s it used for?
The Men’s Comprehensive Cancer Panel provides indicators for the common cancers that affect males. These include cancers of the prostate, testes, large intestine (colon and rectal), stomach, pancreas, liver, and breast.
The primary purpose of the PSA test is to screen for prostate cancer. High levels may indicate an inflamed or enlarged prostate or the existence of prostate cancer. The presence of the carcinoembryonic antigen (CEA) in the blood may indicate certain kinds of cancers, typically colon and rectal, but sometimes pancreas, breast or lung. Similarly, the presence of alpha-fetoprotein (AFP) in men may point toward cancer of the stomach, testicles, pancreas or liver. High levels may indicate Hodgkins disease, brain tumors, renal cell cancer or lymphoma. CA 27-29, CA15-3 and CA 19-9 are tumor markers for breast cancer and pancreatic cancer respectively.
VitaHealth Analysis
Comprehensive Cancer - Male
| Prostate-Specific Antigen (PSA) | Measures the level of prostate-specific antigen (PSA) to evaluate prostate function in men age 40 and older |
| Carcinoembryonic Antigen (CEA) | CEA is associated with certain kinds of cancers, especially colon and rectal cancer. Elevated CEA levels are also found with other cancers including pancreatic, gastric, lung, ovary, and breast |
| a-Fetoprotein (AFP), Tumor Marker | AFP (Alpha-Fetoprotein) in the blood can indicate certain types of cancer, especially cancer of the liver, testicles, ovaries, stomach, or pancreas |
| Carbohydrate Antigen (CA) 19.9 | The Cancer Antigen 19-9 (CA 19-9) blood test is a powerful tool for the detection of pancreatic or gastrointestinal cancer |
| Cancer Antigen (CA) 27.29 | Along with being the premier blood test for breast cancer, the CA 27.29 also detects additional associated malignancies in colon, gastric, hepatic, lung, pancreatic, ovarian, and prostate cancers |
| Cancer Antigen 15-3 | This cancer antigen test may help in seeing how much cancer may be present in the body. This test is commonly ordered with CA 27.29 as they are related to each other and used with other clinical evaluations to monitor cancer treatment |